Connect with us

Media & Technology

The Powerful Run on Northwest Biotherapeutics, Inc (OTCMKTS: NWBO)

Published

on

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) has emerged as one of the most exciting stories in small caps in recent months seeing its stock skyrocket from $0.14 lows earlier this year to recent highs of $2.51 per share. For years NWBO showed huge promise but the stock went nowhere and attracted many long suffering longs who are now up at least 7 X their money.

NWBO recently saw a powerful move as the Company reported Data Lock for the Phase III trial of DCVax®-L for Gliobastoma. This comes after a long 13 – year wait for investors. Expectations are sky high for DCVax-L; unique because it doesn’t target one particular antigen, but uses the patient’s own tumour specimen to create the vaccine. Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer and represents a potential market expected to reach $1.4 billion by 2025. A cornerstone of NWBO expanding program is completion of the buildout of the Sawston, UK manufacturing facility.

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.  NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines. NW Bio recently completed the acquisition of Flaskworks for $4.33 million, of which $1.65 million was paid in cash at closing. Flaskworks has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax®.  It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. Flashworks technical team has joined NW Bio as part of the acquisition.

NW Bio lead product, DCVax-L, is in Data Lock for the Phase III trial of DCVax®-L for Gliobastoma. Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.

NW Bio second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.  NW Bio previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Many, many patients have claimed DCVAX saved their lives including Alice a Metastic Merkel Cell patient from Florida. Brad Silver a GBM patient from Huntington Beach, California. Sarah Rigby a GBM patient from Hong Kong. Kristyn Power, the daughter of GBM patient from Canada. Kat Charles GBM patients from UK as related by her husband Jason (Kat’s Cure)

To Find out the inside Scoop on NWBO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

NWBO

There have also been many media stories about DCVAX saving people’s lives including articles in NBC Channel 4 and a number of print magazines. NWBO – National Geographic’s Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson. NWBO GBM Brain Cancer Survival Story of Mark Pace. NWBO GBM Brain Cancer Suvivial Story of Brad Silver. NWBO, GBM Brain Cancer Survival Story of Mike Gregoire. UCLA – Real Stories Using DCVax.

On October 5 NWBO announced the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked. With the database now locked, the independent service firms managing the Clinical Trial are arranging for the independent statisticians to have access to the unblinded raw data from the Trial.  Neither the Company nor any party other than the independent statisticians will have access to any unblinded data at this stage.

NWBO CEO Linda Powers stated: “We are excited to be so close to the finish line now, after such a long road. We are hopeful that DCVax®-L can become an important new treatment option for patients who urgently need more and better treatments for Glioblastoma brain cancer. We are grateful to the independent service firms and the clinical trial sites who have worked so hard to complete the data collection and confirmation during many months of COVID restrictions and challenges. We are also very grateful to our shareholders for their patience and support, which has made all this possible.”

Linda Powers previously stated “The UCLA Brain Tumor Program continues to shine as a beacon of hope, carrying a record of patients with brain tumors living longer than patients treated at any other hospital. Our personalized brain cancer vaccine, DCVax, is the first of its kind and is currently in Phase III clinical trials in 46 centers throughout America. It is on the road to FDA approval as well as clinical trials throughout Europe.  Using this vaccine, we are harnessing the patient’s immune system, genetics, pathology, brain mapping and a wide database of bioinformatics to optimize outcomes.”

https://twitter.com/KauriCapital/status/1327499596810100741

 

For the very latest on  NWBO Subscribe Right Now!

NWBO has emerged as one of the most exciting stories in small caps in recent months seeing its stock skyrocket from $0.14 lows earlier this year to recent highs of $2.51 per share. For years NWBO showed huge promise but the stock went nowhere and attracted many long suffering longs who are now up at least 7 X their money. NWBO recently saw a powerful move as the Company reported Data Lock for the Phase III trial of DCVax®-L for Gliobastoma. This comes after a long 13 – year wait for investors. Expectations are sky high for DCVax-L; unique because it doesn’t target one particular antigen, but uses the patient’s own tumour specimen to create the vaccine. Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer and represents a potential market expected to reach $1.4 billion by 2025 as NWBO are well aware of. A cornerstone of NWBO expanding program is completion of the Phase I buildout of the Sawston, UK manufacturing facility. It has been noted that after all this data and blinded information readily available, a redefined SAP that allows for comparison to contemporaneous trials, and even if the worse-case scenario of the overall survival not meeting the two month increase, there is still enough positive outcomes from this trial that this would readily provide Linda Powers and her board ample bargaining power to sell NWBO’s proprietary vaccine to the highest bidder, which would readily be in the $10 to $20 billion market cap range.” Microcapdialy has been covering NWBO since the stock was $0.15 per share. We will be updating on NWBO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with NWBO.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NWBO either long or short and we have not been compensated for this article.

Continue Reading
4 Comments

4 Comments

  1. Chris Lonsford

    November 15, 2020 at 7:35 pm

    Recent high was 2.51 not 0.51

    • Justin Kinney

      November 15, 2020 at 7:40 pm

      Thanks Longsford. Anyone else have anything to add?

  2. joe pratt

    November 15, 2020 at 10:24 pm

    https://www.dropbox.com/sh/tlagm94xvkr4eah/AADYWl2TLEu9wzG5P1-nPp9ja?dl=0&preview=Cognate+PILOT+Application.pdf

    By Greg Akers – Editor-in-Chief, Memphis Business Journal
    Nov 13, 2020, 3:04pm CST Updated Nov 13, 2020, 3:29pm CST
    A bioscience company with a large local presence is planning a new investment that would create hundreds of jobs and see three industrial sites receive major renovations and new construction.

    Cognate BioServices Inc. plans to renovate three properties for “cell-therapy operations, contract development, and manufacturing for drug sponsors, and related logistics.”

    The company is seeking a 15-year Jobs PILOT (payment-in-lieu-of-taxes) from the Economic Development Growth Engine (EDGE) for Memphis and Shelby County. The incentive would be worth $52 million, and be based on a $212 million project investment.

    The investment would include $126 million in construction costs and $71 million in personal property. It covers sites at 4600 E. Shelby Drive, 5780 E. Shelby Drive, and 6100 Global Drive.
    See ihub 330449
    https://microcapdaily.wpengine.com/the-powerful-run-on-northwest-biotherapeutics-inc-otcmkts-nwbo/128611/

  3. joseph H pratt

    November 15, 2020 at 10:26 pm

    ae kusterer Sunday, 11/15/20 09:24:24 PM
    Re: None 0
    Post #
    330550
    of 330554

    COULD IT BE THAT NWBO WILL LICENSE THE FLASKWORKS TECHNOLOGY TO COGNATE?

    https://nwbio.com/northwest-biotherapeutics-acquires-flaskworks-breakthrough-automation-technology-for-cell-therapy-products-to-enable-scale-up-of-production-volumes-and-reduction-of-production-costs/

    “The Flaskworks system will follow the same batch-manufacturing process – doing so in a “closed” and automated manner.

    Certain optimization work will be required so that the Flaskworks system will produce DCVax-L products with characteristics equivalent to the products made by the current DCVax-L manufacturing processes. This will then need to be confirmed by comparability studies. The Flaskworks technical team will work with NW Bio’s contract manufacturers to accomplish this. In the meantime, the Company’s DCVax products will continue to be made through the existing processes.”

    https://www.dropbox.com/sh/tlagm94xvkr4eah/AADYWl2TLEu9wzG5P1-nPp9ja?dl=0&preview=Cognate+PILOT+Application.pdf

    http://www.growth-engine.org/news/events/wednesday-november-18-2020-edge-board-meetings/

    https://www.bizjournals.com/memphis/

    KaOsiris Friday, 11/13/20 04:57:54 PM
    Re: None 0
    Post #
    330131
    of 330199
    Cognate BioServices plans $212M investment in Memphis ops

    Memphis Business Journal

    By Greg Akers
    Editor-in-Chief, Memphis Business Journal
    Nov 13, 2020, 3:04pm CST
    Updated 26 minutes ago

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

MSP Recovery (NASDAQ: LIFW) in the Spotlight: Legal Battles, Luxe Living, and Stock Surge

Published

on

MSP Recovery (NASDAQ: LIFW) has been on quite the rollercoaster ride, defying gravity with over 400% gain since September 14th, 2023 with over 240% of that gain happening this week alone. However, the exact reasons behind this meteoric rise remain elusive. Typically, when a company drops major news, you’d expect an instant stock reaction. But in this case, the last significant update from the company was about a week ago, and it’s questionable whether that news was much on the positive side, yet the stock is still zooming upwards.

Background:

Let’s delve into the nitty-gritty of what MSP Recovery, more prominently known as LifeWallet, is all about. Imagine them as the healthcare financial detectives, diligently sifting through the complexities of medical billing and reimbursements. They specialize in recovering money owed to healthcare providers. If an insurance company owes a hospital for a patient’s treatment, these folks ensure that the hospital gets the rightful compensation. But their innovation doesn’t stop there.

Enter “LifeWallet,” their brainchild—a powerful tool designed to revolutionize healthcare transactions. Picture it as a savvy assistant for healthcare professionals, standing by their side in the hustle and bustle of medical care. LifeWallet’s magic lies in its ability to decipher the complexities of healthcare billing and insurance. It guides doctors and hospitals, helping them navigate the tangled web of who should foot the bill, especially in post-accident treatments. It’s a digital ally ensuring fair compensation and smooth financial transactions in the intricate healthcare landscape.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

MSP is making waves in the healthcare domain with this innovative approach, leveraging data analytics to streamline processes and champion fair compensation for healthcare providers. Much like a rollercoaster ride, their journey promises excitement, surprises, and an undeniable thrill in the world of healthcare finances.

Legal Battles and CEO Extravagnce:

Step back and look at their stock chart—MSP has taken a major hit in value this year, and it’s not without reason. Surprisingly, digging into the company’s operations revealed some unpleasant surprises we hadn’t anticipated. It’s been a rough ride for them.

The company was just recently involved in a class action law suit led by recognized leader in shareholder rights litigation, Robbins LLP. The case revolved around MSP not providing essential information to investors transparently.

There were a number of claims mentioned, here’s a quick list.

  1. MSP didn’t reveal there was an ongoing investigation by the SEC and federal prosecutors.
  2. They gave out financial information to investors that was significantly wrong and deceptive.
  3. When admitting they needed to fix their financial results, they didn’t reveal the full extent of the issues.
  4. MSP couldn’t financially handle the claims they were assigned to manage by a major health and engaged in deceitful actions with said provider
  5. The Registration Statement had lots of wrong or misleading statements and was poorly prepared.
  6. Their Proxy also had false or misleading statements.

It all started on July 31, 2023, where The Miami Herald unveiled significant revelations. Stating the CEO John H. Ruiz has been living quite the lifestyle buying several waterfront mansions in Miami, even an entire Boeing passenger jet.

It’s not surprising the Ruiz’s lifestyle was so extravagant considering LifeWallet was once valued at more than $32 billion, but as you can see the company is now worth a small fraction of that. That said, Ruiz’s expensive lifestyle would be tough to continue.

Then again, on August 1, 2023, the Company made disclosures to the SEC (Form 8-K), confirming The Miami Herald’s findings. The stock took another substantial hit, dropping over 12%. Adding to the unfolding drama. After that, a substantial $67 million lawsuit was filed against the Company on the same day, resulting in an 18% plummet in the stock price.

The narrative continues on! On August 17, 2023, MSP acknowledged a notification letter from Nasdaq’s Listing Qualifications Department. They confirmed the Company’s non-compliance with Nasdaq’s Rule 5250(c)(1) due to a delayed Form 10-Q filing for the period ending June 30, 2023. This revelation caused a 19% stock price drop over two days.

With that said, we’ll bet you’re seriously wondering how could this company could possibly see recovery (pun intended) after all these allegations were laid out.

What happened:

Surprisingly enough, it seems Robbins LLP just recently lost the case against MSP and there was an announcement made on September 13th, 2023 about it. All those allegations have vanished into thin air. It’s baffling how a company with so many strikes against it can seemingly wrap things up so quickly. The whole situation leaves us questioning what’s really going on.

Since the announcement the other week, the company’s valuation has skyrocketed, at some points even peaking at an increase of over 400%. Naturally with that kind of trading action, it’s no surprise day traders are getting in on the action. MSP is trending all over Twitter amongst notable users like @timothysykes, @stockplaymaker1, and @AngryRed316 talking about it.

At this point, it looks like investors are basing their trades more on chart patterns and less on the company’s solid financial footing. MSP didn’t deliver great news in its latest earnings report, showing quite a large net loss of over $400 million. It’s quite likely the allegations had a role to play in this financial blow. The real question is if MSP can get its act together, start making real profits, and avoid a chapter 11. Either way, we’ll continue to follow along to see how things pan out!

We will update you on LIFW when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture geralt by from Pixabay.com

 

Continue Reading

Featured

VCI Global (NASDAQ: VCIG) Joins Forces with Microsoft Azure OpenAI: A Tech Revolution Unleashed

Published

on

VCI Global (NASDAQ: VCIG) is back on the radar with another significant gain of 84%. We wrote about this company just recently in June, where it popped 156% on the announcement of their “Socializer Messenger”. The company is now teaming up with Microsoft Azure OpenAI through its subsidiary, V Galactech Sdn Bhd. This partnership brings together their AI know-how to reshape the world of business solutions, making waves in the tech scene by using Microsoft Azure OpenAI services.

This collaboration is all about meeting the growing demand for tech advancements that are fast, smooth, and globally connected, helping businesses connect better with their customers. It’s also a boost to VCI Global’s AI consulting skills.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

By tapping into what Microsoft Azure OpenAI offers, VCI Global is jumping into the tech world’s fast lane. They plan to come up with some cool innovations, like Generative Pre-trained Transformer 4 (GPT-4) and Microsoft’s new AI-powered chat tool, Bing Chat Enterprise. Plus, they’ll use Microsoft Azure OpenAI’s cutting-edge AI for their projects, including the super-smart AI-assisted sales platform, robosale software.

https://twitter.com/ShortDaPos/status/1694403174566858783?s=20

Dato’ Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global, is very excited about this partnership. He mentions, “We’re thrilled to dive deep into AI innovations, especially with Microsoft Azure OpenAI. We can’t wait to see how this partnership transforms how businesses connect with customers in the ever-changing tech world. The sky’s the limit, and we’re ready to help our clients ride this AI wave.”

About VCI Global Limited:

VCI Global is a versatile consulting group that’s all about helping businesses with their tech and strategy. They give advice on business strategies, help with investor relations, and provide tech know-how. They mainly work in Malaysia, but they also serve clients in Malaysia, China, Singapore, and the United States, covering a bunch of different industries.

If you want to know more about them, just head to https://v-capital.co/.

About Microsoft Azure Open AI:

Microsoft Azure OpenAI is like a treasure chest of artificial intelligence tools and solutions made to help businesses. They offer everything from AI Services to Machine Learning and AI infrastructure, all aimed at helping businesses make the most of AI for their growth and innovation.

We will update you on VCIG when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Mohamed_hassan from Pixabay

Continue Reading

Featured

Mobilicom (NASDAQ: MOB) Secures Landmark Deal with Top Global Manufacturer

Published

on

Mobilicom (NASDAQ: MOB), a company providing cybersecurity and reliable solutions for drones and robotics secures its largest order to date from Teledyne Technologies Incorporated (NYSE: TDY) – shares rocket 123%. $TDY is one of the world’s largest manufacturers of small-sized drones and robotics.

Overview:
This $19B Tier-1 customer has now incorporated Mobilicom’s SkyHopper PRO into its latest small-sized drone platform. This is yet another testament to Mobilicom’s systems as they have already successfully integrated into 44 design wins by various drone and UAV manufacturers.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

More importantly, Teledyne has made significant progress in transitioning from the design phase to production and commercial sales with the U.S. Department of Defense. The company’s latest purchase order appears to reflect only the beginning of potentially multiple recurring orders as they prepare for their first-ever production order for the U.S. DOD.

“As Teledyne-FLIR continues to win additional orders for its small-sized drone platforms with end users such as the U.S. DOD, other federal agencies, and commercial customers, Mobilicom is well positioned for more sales of its Skyhopper Pro,” stated Mobilicom CEO Oren Elkayam. “We see the sales of these systems to the U.S. DOD, one of the largest and most selective procurers of technology, as a strong testament to the excellence of Mobilicom’s market-leading end-to-end solutions.”

 

About SkyHopper PRO:
The SkyHopper PRO is a communication system for drones that ensures secure data transfer. It offers a number of advantages and customization compared to competitors, here’s a quick overview:

Cybersecurity: Prioritizes cybersecurity, ensuring the secure transfer of data between the drone and the ground control station. This feature helps protect sensitive information and prevents unauthorized access or interference.

Reliability: The system is designed to provide robust and reliable communication even in challenging environments. It supports long-range and non-line-of-sight communication, enabling seamless connectivity between the drone and the ground station, even when obstacles are present.

Versatility: Supports multiple transmission modes, including point-to-point and point-to-multipoint communication. This versatility enables various communication setups, such as multi-drone operations and communication to multiple receivers, enhancing flexibility in drone missions.

Industry Integration: Systems have been integrated into numerous design wins by drone and UAV manufacturers indicating their compatibility and suitability for a wide range of platforms. The proven track record of integration demonstrates the system’s adaptability and reliability.

End-to-End Solution: End-to-end solutions for cybersecurity and robust communication. This comprehensive approach ensures seamless integration, streamlined operations, and enhanced overall performance for drone missions.

About Mobilicom:
Mobilicom is a leading provider of end-to-end cybersecurity and robust solutions for drones and robotics. They focus on serving global manufacturers in these industries, offering patented Mobile Mesh networking technology and a proven portfolio of commercialized products. With a growing high-profile global customer base, including corporations, governments, and the military, Mobilicom stands out for its outstanding security capabilities and performance in harsh environments. They derive revenue from hardware and software sales, licensing fees, and professional support services.

About Teledyne Technologies (NYSE: TDY):
Teledyne Technologies is a global leader known for its innovative solutions in aerospace and defense, environmental sensing, and digital imaging. The company’s success stems from a strong emphasis on research and development, enabling them to introduce cutting-edge technologies and meet customer needs effectively. With a focus on quality and customer satisfaction, Teledyne Technologies has earned a solid reputation in the industry. Strategic acquisitions have further strengthened their capabilities, expanding their product offerings and market reach. Through adaptability and a commitment to delivering value, Teledyne Technologies has established itself as a prominent player in various verticals in multiple industries, ultimately paving the way for the company’s current $19B stature in the market.

We will update you on MOB when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Pexels from Pixabay

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.